Google
VTRS Stock Analysis — VIATRIS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
VTRS FAQ
What is VTRS's P/E ratio?
VIATRIS INC (VTRS) currently trades at a P/E ratio of 117.25.
What is VTRS's ROE?
VIATRIS INC reports a Return on Equity (ROE) of -2.02%.
What is VTRS's dividend yield?
VIATRIS INC offers a dividend yield of 2.69%.
What is VTRS's Quality Score?
Our AI rates VTRS's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy VTRS?
Our AI Timing Score for VTRS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does VTRS belong to?
VIATRIS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange
VTRS AI Analysis Summary
Our AI summary for VTRS: VIATRIS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 117.25, ROE of -2.02%, a dividend yield of 2.69%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 17.56
Price
-0.20
(-1.13%)
Day Change
|
|
|---|
VTRS, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 17.56 |
| PBV / Sector |
1.41 / 3.22
GOOD
|
| Earning Per Share | -0.25 |
| PE / Sector |
117.25 / 29.79
|
| PEG or PE/Growth / Sector |
-0.39 / 0.13
|
| Average 1M Daily Value |
153.47 M
GREAT
|
| Average 1W Daily Value |
174.32 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
50% |
| Return to Investors |
|
33% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:41 |
| Symbol | VTRS |
| Name | VIATRIS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 1,164.55 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 20,682.46 / 10,754.62 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Robert J. Coury Global Center, Canonsburg, PA, United States, 15317
Phone: 724 514 1800
Website: https://www.viatris.com
Employees: 30,000
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Drug Manufacturers - Specialty & GenericAnalysed on the same criteria, ordered by market cap